Fenofibrate significantly lowered triglyceride levels compared to omega-3 in pediatric patients with hypertriglyceridemia (p=0.014).
RCT (n=30)
Open-label
parallel-group
No
Does fenofibrate reduce triglyceride levels compared to omega-3 in pediatric patients with hypertriglyceridemia?
Fenofibrate 100 mg daily significantly reduced triglycerides, LDL-C, and total cholesterol compared to omega-3 in pediatric patients with hypertriglyceridemia.
p-value: p=0.014
INTRODUCTION Concerning the growing prevalence of hypertriglyceridemia in pediatrics, further investigation into their use in children is warranted. This study aimed to evaluate the efficacy and safety of fenofibrate compared to omega-3 in pediatric hypertriglyceridemia. METHODS This open-label, parallel-group randomized controlled trial was performed in 17 Shahrivar Hospital in Rasht, Iran, from January to June 2023. This included individuals aged 8 to 18 with TG levels >400 mg/dL or >250 mg/dL unresponsive to diet and exercise. Patients (N = 30) were randomly assigned to receive either fenofibrate (100 mg daily) or omega-3 (1,000 mg twice daily) for 12 weeks. RESULTS Fenofibrate treatment significantly lowered triglyceride (TG), Low-density lipoprotein-cholesterol (LDL-C), and total cholesterol levels compared to omega-3 (p = .014, p < .001, and p < .001, respectively). The omega-3 group exhibited an upward trend in high-density lipoprotein-cholesterol (HDL-C) levels (p = .004), and intergroup differences were statistically significant (p = .038). DISCUSSION Fenofibrate appeared to be a safe and effective candidate for TG lowering in pediatrics with hypertriglyceridemia, though further clinical research is recommended.
Dalili et al. (Sun,) conducted a rct in pediatric hypertriglyceridemia (n=30). fenofibrate vs. omega-3 (1,000 mg twice daily) was evaluated on triglyceride (TG) levels (p=0.014). Fenofibrate significantly lowered triglyceride levels compared to omega-3 in pediatric patients with hypertriglyceridemia (p=0.014).